Trial Profile
Phase 1 Study of Single Agent BAY 86-9766 in Japanese Patients With Advanced or Refractory Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2017
Price :
$35
*
At a glance
- Drugs Refametinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 21 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.
- 28 Feb 2012 Planned end date changed from 1 Mar 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.